Seeking Alpha

MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Actinium Pharmaceutics, Inc. (ATNM) Engages Goodwin Biotechnology To Supply Iomab™-B For Its Phase 3 Clinical Study 0 comments
    Jan 29, 2014 2:22 PM | about stocks: ATNM

    Today before the opening bell, Actinium Pharmaceutics reported that it has engaged Goodwin Biotechnology in a manufacturing supply agreement. In this agreement, Goodwin Biotechnology will be the overseer of the current Good Manufacturing Practices production of a monoclonal antibody that is expected to be used in an upcoming phase 3 clinical trial of Iomab™-B. Iomab™-B is to be used in preparation of patients for hematopoietic stem cell transplant (HSCT), which is commonly referred to as a bone marrow transplant (BMT).

    "This agreement with Goodwin Biotechnology represents a major risk mitigation step in conducting our phase 3 trial of Iomab™-B," said Kaushik J. Dave, President and CEO of Actinium. "Goodwin Biotechnology has significant experience in working with companies like ours and the capabilities to provide the scale-up needed for a late-stage clinical trial. Its competencies in process and product implementation, quality assurance, and GMP manufacturing make it ideally suited as a manufacturing partner for Actinium as we look forward to launching this pivotal phase 3 trial later this year."

    "We are very excited to be working with Actinium on Iomab™-B, their lead product candidate," said Karl Pinto, CEO of Goodwin Biotechnology. "Actinium's cutting edge proprietary platform is able to target different types of cancers that are without any approved treatment options. We look forward to a long-term partnership with Actinium, not only on Iomab™-B, but hopefully also on other products in their pipeline such as Actimab-A."

    Based out of New York, Actinium is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Currently, it is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B. In that study, the radioimmunoconjugates and its treatment efficacy are being examined in refractory and relapsed Acute Myeloid Leukemia (AML) patients, who are over 55 years of age, with a primary endpoint of durable complete remission.

    For more information on Actinium, visit:

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit

    Stocks: ATNM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.